At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02137 BRII-B
Noon Closed 07-14 11:55:02
0.980
-0.040
-3.92%
High1.000Low0.980Vol238.00K
Open1.000D1 Closing1.020Amplitude1.96%
Mkt Cap707.56MTradable Cap707.56MTotal Shares722.00M
T/O235.42KT/O Rate0.03%Tradable Shares722.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Brii Biosciences (BRII-B) Adds 46.56 Thousand New Shares in June; Confirms Public-Float Compliance
Bulletin Express  ·  07-07
Brii Biosciences (BRII-B) Adds 46.56 Thousand New Shares in June; Confirms Public-Float Compliance
Is Brii Biosciences (HKG:2137) In A Good Position To Deliver On Growth Plans?
Simply Wall St.  ·  07-04
Is Brii Biosciences (HKG:2137) In A Good Position To Deliver On Growth Plans?
Brii Bio Announces Topline End-of-treatment Data from Phase 2B Enrich and Enhance Studies for the Treatment of Chronic Hepatitis B
THOMSON REUTERS  ·  07-03
Brii Bio Announces Topline End-of-treatment Data from Phase 2B Enrich and Enhance Studies for the Treatment of Chronic Hepatitis B
BRII-B Reports End-of-Treatment Topline Data from Phase 2b ENRICH and ENHANCE Studies for Chronic Hepatitis B
Stock News  ·  07-03
BRII-B Reports End-of-Treatment Topline Data from Phase 2b ENRICH and ENHANCE Studies for Chronic Hepatitis B
Brii Biosciences Says Arbitration with Vir Clouds Future of Elebsiran Program
Reuters  ·  07-03
Brii Biosciences Says Arbitration with Vir Clouds Future of Elebsiran Program
Wuxi XDC Appoints Yuan Fang Joint Company Secretary, Authorized Representative
Reuters  ·  06-26
Wuxi XDC Appoints Yuan Fang Joint Company Secretary, Authorized Representative
HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%
Tiger Newspress  ·  06-23
HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%
Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Reuters  ·  06-17
Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
BRII-B Announces Share Buyback Initiative
Stock News  ·  06-17
BRII-B Announces Share Buyback Initiative
Brii Biosciences Announces HK$60 Million On-Market Share Buy-back, Capping at 10% of Issued Shares
Bulletin Express  ·  06-17
Brii Biosciences Announces HK$60 Million On-Market Share Buy-back, Capping at 10% of Issued Shares
Brii Biosciences - to Buy Back up to 10% of Issued Shares
THOMSON REUTERS  ·  06-17
Brii Biosciences - to Buy Back up to 10% of Issued Shares
Brii Biosciences Ltd - Share Buy-Back Programme Is No More Than HK$60 Mln
THOMSON REUTERS  ·  06-17
Brii Biosciences Ltd - Share Buy-Back Programme Is No More Than HK$60 Mln
Brii Biosciences shareholders adopted resolutions at annual general meeting, poll results show
Reuters  ·  06-16
Brii Biosciences shareholders adopted resolutions at annual general meeting, poll results show
HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%
Tiger Newspress  ·  06-05
HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%
Brii Bio says Phase 2 ENSURE trial shows higher HBV functional cure rate with elebsiran plus pegylated interferon alfa
Reuters  ·  05-27
Brii Bio says Phase 2 ENSURE trial shows higher HBV functional cure rate with elebsiran plus pegylated interferon alfa
BRII-B (02137) and Vir Yet to Settle Claims in Ongoing Dispute
Stock News  ·  05-22
BRII-B (02137) and Vir Yet to Settle Claims in Ongoing Dispute
BRII-B Initiates Arbitration Against Vir Biotechnology, Casting Uncertainty Over Elebsiran Hepatitis B Program
Bulletin Express  ·  05-22
BRII-B Initiates Arbitration Against Vir Biotechnology, Casting Uncertainty Over Elebsiran Hepatitis B Program
Brii Biosciences Ltd - as of May 22, Arbitration Between Brii and Vir Remains in Early Stages With No Resolution
THOMSON REUTERS  ·  05-22
Brii Biosciences Ltd - as of May 22, Arbitration Between Brii and Vir Remains in Early Stages With No Resolution
Brii Biosciences Ltd - Considers Elebsiran Program Future Uncertain Due to Ongoing Dispute
THOMSON REUTERS  ·  05-22
Brii Biosciences Ltd - Considers Elebsiran Program Future Uncertain Due to Ongoing Dispute
Brii Biosciences - Cannot Invest in Phase 3 Clinical Study of Any Elebsiran-Containing Combination Therapy for Hbv Until Claims Are Resolved
THOMSON REUTERS  ·  05-22
Brii Biosciences - Cannot Invest in Phase 3 Clinical Study of Any Elebsiran-Containing Combination Therapy for Hbv Until Claims Are Resolved

Introduction

Company Name.
BRII-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Brii Biosciences Ltd is a biotechnology company primarily engaged in the development of therapies for infectious diseases and central nervous system diseases. The Company's main products include BRII-179, a candidate drug for hepatitis B virus (HBV) immunotherapy, Tobevibart, an investigational neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg), as well as soralimixin (BRII-693), a synthetic lipopeptide for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacterial infections. The Company primarily operates its businesses in the domestic market.
Issue price:
--